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Abstract
The long term consequence of immunosuppressive 
therapy in kidney transplantation has prompted inves-
tigation of alternative means to modify the immune 
response to the allograft. Cell based therapies are 
potentially attractive as they may provide a long last-
ing immunomodulatory effect, may repair tissues and 
reduce the necessity to take immunosuppressive drug 
therapy. Of the current cell therapies, mesenchymal 
stem cells have now been trialled in small numbers 
of human kidney transplantation with apparent safety 
and potential efficacy. Many issues however need to be 
resolved before these cells will become mainstays of 
transplant immunosuppression including ex vivo  modi-
fication to enhance immunomodulatory properties, cell 
number, route and frequency of administration as well 
as cellular source of origin.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This review summaries several of the most 
prominent cellular therapies currently being examined 
for use in immunosuppression. From the current evi-
dence the reviewers make the argument that mesen-
chymal stem cells offer the best chance of a useful and 
functional cellular therapy for solid organ transplanta-
tion.
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INTRODUCTION
Kidney transplantation remains the optimal treatment 
for end stage renal disease (ESRD) providing excellent 
short term outcome with greater quality of  life than 
that provided by dialysis[1]. Whilst short term graft sur-
vival is improving and acute rejection rates are dropping 
long term graft survival rates remain a major focus for 
clinical improvement.  There are many factors that can 
impact the prognosis of  a kidney transplant, from graft 
or donor considerations[2,3], factors involving the im-
munosuppressant regime[4,5], and issues concerning the 
recipient[6,7]. 
Tissue typing and stringent exclusion criteria are 
implemented pre-transplant to reduce the risk of  donor 
related problems[3]. Issues with the recipient such as non-
compliance and co-morbidity are much more difficult to 
manage and are often beyond a clinician’s power to con-
trol[6,7].
When a suitable kidney donor is found, it is then 
important to make sure that the graft does not reject 
by suppressing the recipient’s immune system. Current 
immunosuppressive drugs may be classified into five 
groups based on their mechanism of  action: (1) regula-
tors of  gene expression; (2) alkylating agents; (3) inhibi-
tors of  de novo purine synthesis; (4) inhibitors of  de 
novo pyrimidine synthesis; and (5) inhibitors of  kinases 
and phosphatases[5]. Targeting each of  these mecha-
World Journal of




World J Clin Urol 2014 July 24; 3(2): 87-95
ISSN 2219-2816 (online)
© 2014 Baishideng Publishing Group Inc. All rights reserved.
July 24, 2014|Volume 3|Issue 2|WJCU|www.wjgnet.com 87
Lett B et al . Mesenchymal stem cells for kidney transplantation
nisms has its benefits and disadvantages and tailoring 
a drug schedule has the potential to impact long term 
graft function and the quality of  life of  the recipient. 
However all current drugs are associated with a range 
of  adverse effects including renal toxicity, opportunistic 
infections, development of  malignancy and metabolic 
complications[5]. A common trait among all these drug 
classes is the targeting of  T cell function[5,8-10]. T cells 
play an important role in rejection via alloantigen rec-
ognition and the direction of  an effector response that 
results in graft damage and dysfunction[11].
Of  these issues it is the modification of  immuno-
suppression that is an obvious place to try and improve 
patient outcomes, as more options will allow for custom-
ised treatment programs unique to each patients needs. 
Towards this end, there has been a recent increase in the 
development of  alternative means of  immunosuppres-
sion for organ transplantation. Utilizing cell-based thera-
pies for immunosuppression is an alternative approach 
to traditional pharmacological methods and represents a 
change in paradigm for transplantation therapies. 
CELL THERAPIES FOR ORGAN TRANS-
PLANTATION
The basic concept of  cell therapy is to implant cells with 
desired properties into a patient in an attempt to treat 
or cure. Although this idea has been around since the 
19th century, it was not until 1968 that it became a viable 
treatment with the first bone marrow transplant[12]. Since 
then, there has been a steady expansion in the type of  
cells transplanted and the conditions that can be treated. 
The purpose of  this review is to examine the state of  
several cell types that are being evaluated for preclinical 
or early clinical trials in solid organ transplantation (SOT), 
including; T regulatory cells (Tregs), dendritic cells (DCs), 
and with a particular emphasis on mesenchymal stem 
cells (MSCs) which have shown the greatest progress 
and potential as a cellular therapy.
RGULATORY T CELLS 
Tregs are naturally occurring T cells which express the 
cell surface markers CD4+CD25+ FoxP3+ and a variety 
of  differing cell surface markers (CD127, Helios)[13,14]. 
Tregs are concerned with the maintenance of  immuno-
logical self-tolerance by suppressing self-reactive lym-
phocytes that escape clonal deletion[14]. Naturally occur-
ring Tregs are formed from naive T cells in the thymus. 
However these naive T cells can be converted to Tregs 
in vitro using TGF-b induction of  FoxP3[15], providing a 
second source of  Tregs for cell therapy. 
Tregs are able to suppress the immune system on 
many levels, combining inhibitory cytokine secretion(e.
g., via TGF-b, IL-10)[16,17], cytotoxicity and inhibition of  
NK cells[18,19], and direct modulation of  antigen present-
ing cells[20-22]. This multifaceted approach to immunosup-
pression makes Tregs a promising therapy to facilitate 
long term graft survival. Recently there have been ad-
vances in the methods for Treg isolation and expansion, 
with large scale expansion from peripheral blood (PB), 
umbilical cord blood (UBC), and induced Tregs from na-
ive peripheral blood precursors[23]. There have also been 
positive results from experimental animal models[24]. Of  
greatest interest are the clinical trials that have used Tregs 
as a cellular therapy in graft-vs-host disease (GVHD), a 
major and potentially lethal transplant complication that 
is particularly prevalent in patients who have undergone 
a hematopoietic stem cell transplant (HSTC)[25,26]. With 
generally positive outcomes from the GVHD trials[26], 
it is likely that we will see Tregs initially deployed as an 
adjunctive therapy in SOT before being used in patients 
who have a high risk of  rejection or who have already 
experienced adverse effects from standard immunosup-
pression. This would allow for the efficacy of  Tregs to 
be determined in a way that would be ethical and pose a 
minimal risk of  complications. 
In addition to their safety, there are several other 
important issues that need to be addressed in the pursuit 
of  an effective Treg based therapy. As mentioned above, 
there have been advances in the isolation and expansion 
of  Tregs. These advances go some way to addressing 
the large number of  cells that would be required for 
an effective therapy, with some estimates placing the 
required number at 11 × 108 cells/kg[27]. Another 
concern is the source of  the Tregs. Currently, the 
most appropriate source for therapy is unknown, with 
uncertainty focused on whether alloantigen or antibody 
mediated expansion is the safest and most effective 
method[23]. The stability of  Tregs in vivo has also been 
found to be problematic with studies finding that Tregs 
can lose FoxP3 expression and develop an effector cell 
phenotype, becoming pathogenic[28]. Of  relevance to the 
previous point about the source of  Tregs is evidence 
suggesting that induced Tregs lose FoxP3 expression at a 
much higher rate than natural Tregs[29,30]. These are just a 
few of  the issues surrounding the use of  Tregs for SOT 
that the ONE study (www.theonestudy.org) hopes to 
address. Currently the ONE study is examining the use 
of  polyclonally expanded Tregs and alloantigen driven 
Tregs in kidney transplantation at doses of  1, 3, 6 and 10 
× 106 Tregs/kg. As of  writing this no results have been 
published[23].
DENDRITIC CELLS 
Dendritic cells (DCs) are able to function as antigen pre-
senting cells that drive graft rejection (immunogenic DC) 
or have a role in promoting graft acceptance (tolerogenic 
DC; TolDC) depending on their state[31]. Immunogenic 
DCs cause T cell activation and proliferation with the 
use of  three signals: (1) they present antigens on MHC 
molecules; (2) They provide co-stimulatory molecules; 
and (3) they secrete pro-inflammatory molecules. Only 
when all three signals are present can DCs activate T 
cells[31]. TolDCs are also able to interact with regulatory 
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T cells to promote immune tolerance. The role that DCs 
play in immune tolerance is twofold. Firstly, they play 
a role in the deletion of  self-reactive thymocytes in the 
thymus[32]. Secondly, and of  relevance to transplantation, 
they aid in peripheral tolerance. They do this by the pre-
sentation of  antigens while lacking the co-stimulatory 
molecules required for T cell activation[32,33]. This causes 
T cell unresponsiveness as well as Treg induction[33].
Two strategies for the use of  TolDCs in transplanta-
tion are likely to be applied in the setting of  allotransplan-
tation. The first involves negative immunization by admin-
istering either autologous DCs that have been exposed to 
alloantigens or donor derived DCs, pre-transplant[34]. The 
second method involves the use of  recipient derived DCs 
delivered on the day of  transplantation[35]. Intravenous 
injection of  immature DCs of  either donor or recipient 
origin at the time of  transplantation have prolonged al-
lograft survival in SOT models[36]. There is a large amount 
of  literature on the use of  DCs in pre-clinical experimen-
tal models[36,37]. Clinical trials looking at DCs have been 
carried out in both type-1 diabetes[38] and rheumatoid 
arthritis[39]. This has shown that the use of  DCs for im-
munomodulation is safe and effective. 
Many of  the issues that face Tregs are also pertinent 
in the consideration of  DCs as a cellular therapy. Cell 
dose and the best method for the isolation and expan-
sion of  the cells is uncertain. The use of  either recipient 
derived DCs or donor DCs is yet to be resolved and 
adding additional complexity to this issue is the ques-
tion of  negative immunization vs. recipient derived DCs 
delivered peri-transplant. Again, the ONE study aims to 
answer these questions and early trials of  DCs in SOT 
are ongoing as of  writing this.
MESENCHYMAL STEM CELLS
Mesenchymal stem cells (MSCs) are a multipotent cell 
lineage that has great potential for use in cellular thera-
pies and is already being widely tested in clinical trials. 
www.clinicaltrials.gov currently lists 396 studies using 
MSCs in conditions such as spinal cord injury, diabetes, 
Alzheimer’s disease, and kidney injury. 
The International Society for Cellular Therapy (ISCT) 
has set the minimal criteria for defining MSCs as being 
plastic adherent, capable of  differentiation into osteo-
blasts, adipocytes, and chondroblasts, and expressing 
CD105, CD73, and CD90 while lacking expression of  
CD45, CD34, CD14 or CD11b, CD19, and HLA-DR 
surface molecules[40]. 
MSCs are capable of  being isolated from many tis-
sues including bone, fat, and placenta. When cultured 
they adhere to plastic and have a fibroblast-like appear-
ance, possessing a long, thin body and a small number 
of  protrusions[40]. MSCs have a role in the formation 
and homeostasis of  connective and structural tissues via 
the production of  extracellular matrix, stabilization and 
regulation of  the tissue vascularisation, and the creation 
of  new connective tissue cells[41,42]. In addition to this, 
they also play a role in the immune system by inducing 
tolerogenic[42] properties that can be enhanced by in vitro 
treatment[43]. These roles are able to be exploited to aid 
in regenerative medicine and in immunosuppression. 
Combined with the many tissues from which they can 
be isolated and their ability to remain stable while being 
expanded in vitro[44] it becomes clear why so much work 
is now being carried out using MSCs for a large number 
of  clinical applications.
The immunosuppressive abilities of  MSCs are medi-
ated by either nitric oxide synthase (iNOS) in mice[45,46], 
or indolamine 2,3-dioxygenase (IDO) in humans[46]. 
iNOS results in the production of  nitric oxide (NO) 
which is an immunosuppressive agent in high concentra-
tions[47]. Alternatively, IDO degrades the essential amino 
acid tryptophan thereby resulting in immunosuppres-
sion. The accumulation of  the tryptophan metabolite 
kynurenine is also known to mediate the immunoregula-
tory effects of  MSCs[48].  
The exact mechanisms of  how two pathways cause 
immunosuppression are not fully understood. In addi-
tion to these key factors, there are several immunosup-
pressive molecules secreted by MSCs. These include; 
PGE-2, IL-10, HO-1, PD-L1, and IL-6[49].
In reaction to stimulus from interferon-gamma 
(IFN-g and proinflammatory cytokines, MSCs also se-
crete chemokines and adhesion molecules such as inter-
cellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1)[45]. This results in a close 
proximity of  immune cells allowing the local immuno-
suppressive environment to have a more pronounced 
effect[49].
A substantial amount of  work has been focused on 
the potential for MSCs to treat GVHD. Ringdén et al[50] 
treated 8 patients, who had developed steroid-refractory 
GVHD, with bone marrow derived MSCs. In 6 of  these 
patients acute GVHD ameliorated. The same group 
later went on to perform a phase Ⅱ trial consisting of  
55 patients with acute GVHD. In this trial, 30 patients 
completely recovered from GVHD and a further 9 
showed improvement. None of  the patients developed 
adverse reactions due to the administration of  MSCs[51]. 
Another phase one trial administering MSCs for GVHD 
was carried out by Introna et al[52] This multicentre study 
looked at 40 patients (15 children and 25 adults) with 
steroid resistant GVHD and gave them a median of  3 
third-party derived MSCs infusions. Here it was found 
that the MSCs had a 67.5% T cell mediated response 
rate with a 27.5% complete response, 86 adverse effects 
were reported however most of  these were of  an infec-
tious nature (72.1%) and not due to the administration 
of  MSCs[52]. They concluded that MSCs could safely 
be administered in addition to conventional immuno-
suppression (e.g., cyclosporin, steroid). Despite these 
positive results, there is some concern over a phase III 
clinical trial that failed to meet its primary clinical end 
point (NCT00366145)[53]. In this trial, patients received 8 
infusions of  2 × 106 cells/kg over 4 wk and 4 more infu-
sions administered weekly after 28 d. The trial did not 
meet its primary end point of  a significant increase of  
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complete response of  steroid resistant GVHD. Galipeau 
et al[54] provides a comprehensive failure analysis of  the 
trial. The main conclusion of  this analysis is that there 
are significant differences between the Martin study and 
studies from Europe that could account for the failure, 
in particular the passage number of  the cells used[54]. As 
such, this study is not damning of  MSCs but rather pro-
vides more areas that require examination before they 
can be used more widely. 
Unlike the other cell types, there are now completed 
early clinical trials that have deployed MSCs as a therapy 
for SOT. The largest comes from Tan et al[55] In their 
trial they had 159 kidney transplant patients split into 3 
groups, with 2 groups receiving autologous MSCs with 
either standard dose calcineurin inhibitors (CNIs) or 
low dose CNIs and the control group receiving standard 
dose CNIs and anti-IL-2 receptor antibody. The major 
conclusions from this study were that the MSC groups 
had a lower incidence of  glucocorticoid-resistant rejec-
tion, a faster recovery in renal function, and significantly 
decreased risk of  opportunistic infections than the 
control group[55]. This study also addresses safety con-
cerns over the use of  MSCs as there were no adverse 
reactions reported in either of  the test groups. However 
this trial was not without its problems. It was noted by 
the authors that the number of  rejection episodes in the 
control group was higher than what would be expected. 
This made it appear that the MSC groups performed 
better than standard immunosuppression when this may 
not be the case[55]. Additionally, the major differences in 
graft function were only noticed in the first 2 wk. It is 
conceivable that this was due the regenerative abilities 
of  MSCs repairing the reperfusion injury associated with 
all kidney transplants. And lastly, the major difference in 
opportunistic infections was noted in the MSC and low 
dose CNI group. As there was no control low dose CNI 
group, we cannot be certain that the observed reduction 
in infection is due to MSCs or simply due to the reduced 
use of  immunosuppressive drugs.
In addition to the work from Tan there have been 
several case reports looking at the use of  MSCs in a 
small number of  SOT patients. Perico et al[56,57] have per-
formed two pilot studies looking at the use of  MSCs in 
kidney transplantation in 4 patients. In their first study 
they administered intravenous autologous MSCs 7 d af-
ter transplantation and followed the patients for 360 d. 
From days 7 to 14 post transplant, serum creatinine in-
creased in 1 of  their patients, however acute graft rejec-
tion was excluded via biopsy. They also noted an increase 
in patient Tregs and a decrease in T cell expansion post-
transplant. Long term, both patients showed stable graft 
and the authors concluded that MSC infusion in kidney 
transplant recipients is feasible, allows increase of  Treg 
in the peripheral blood, and controls memory CD8+ 
T cell function[57]. In their second trial, they dosed two 
living-related kidney transplant recipients with autolo-
gous MSCs one day before transplantation. The change 
in dosing time was an attempt to avoid the acute graft 
deterioration observed to be caused by intragraft local-
ization of  MSCs when dosing 7 d post-transplant. Al-
though both patients had no side effects to the MSC in-
fusion and both had stable graft function at 12 mo, one 
of  their patients did have an acute rejection episode 14 
d post-transplant that was resolved with corticosteroid 
therapy[57]. The authors attribute the rejection episode to 
a higher number of  HLA mismatches. They concluded 
that pre-transplant administration of  MSCs avoided 
the cell induced graft dysfunction associated with post-
transplant MSC administration and that this method is 
favourable for future trials. Peng et al[58] examined the ef-
fect of  autologous MSCs on renal transplants by giving 6 
patients MSCs combined with half  doses of  tacrolimus 
and comparing acute rejection, graft function, and graft 
survival at 12 mo to a control group of  6 patients receiv-
ing standard dose tacrolimus. The results of  this showed 
no toxic adverse effects associated with MSC infusion 
and all patients survived with stable graft function to 12 
mo with only 1 acute rejection episode in the control 
group. The one difference they did notice was elevated 
B-cell counts in the MSC group at 3 mo compared to 
the control[58]. They concluded that MSCs may provide 
benefits in renal transplantation by reducing the required 
dose of  conventional immunosuppressive drug that is 
required for long term graft survival.  The results of  
these case reports are consistent with those of  the Tan 
study, with no adverse reactions, stable graft function, 
reduced rejection, and the ability to lower maintenance 
immunosuppression (Table 1). 
From these early clinical trials, summarised in Table 1, 
it is evident that MSCs have an acceptable safety profile 
and have beneficial effects for transplantation. There 
still remain several very important questions to be an-
swered before MSCs can obtain mainstream clinical use. 
The issue of  whether autologous or allogeneic MSCs 
are better is significant, with arguments for both being 
put forward. Tan et al[55] employed autologous MSCs 
because of  the issues surrounding MSC isolation from 
deceased donors. Furthermore, the use of  autologous 
MSCs would avoid any potential for rejection of  the 
cells and a subsequent loss of  their function. However, 
there is some evidence that MSCs are immuno-evasive 
allowing them to escape recognition by the hosts im-
mune system[59]. If  this is the case then allogeneic MSCs 
are promising as obtaining them will not impact the 
eventual recipient who may have serious health issues 
that could be exacerbated by the collection of  MSCs or 
could impact the quality of  the MSCs. The immuno-
evasive status of  MSCs also opens up the potential for 
third party derived MSCs. This would invalidate con-
cerns about obtaining MSCs in the cases of  deceased 
donors. Nevertheless, issues pertaining to the immu-
nogenicity of  allogeneic or third-party derived MSCs 
has not been substantially addressed in vivo and have 
not been addressed in large animal models. There are 
preclinical studies demonstrating that allogeneic MSC 
monotherapy alone failed to prevent allograft rejec-
tion[60-69]. Studies reporting on the benefits of  allogeneic 
MSCs have also shown short term prolongation of  graft 
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survival[64]. More importantly, in some studies, pre-trans-
plant allogeneic MSC monotherapy accelerated allograft 
rejection thereby questioning the immunoprivileged 
status of  MSC. There is evidence that allogeneic MSCs 
can trigger an anti-donor immune response resulting 
in accelerated allograft rejection[65-67]. The co-admin-
istration of  allogeneic MSC with immunosuppressive 
drugs however showed better outcome of  the allograft 
compared to MSC monotherapy[63,64,70-72]. Therefore, the 
synergistic effects of  allogeneic MSC with immunosup-
pressive drugs need to be taken into consideration in 
MSC therapy. We have previously reviewed in detail the 
mechanisms associated with allogeneic or third-party 
derived MSC immunogenicity and the synergistic effects 
of  MSC with immunosuppressive drugs, in Sivanathan 
et al[43]. Questions around the dose rate, the timing, the 
route of  administration, what happens to the cells and 
what exactly the MSCs are doing and their mechanism 
of  action still remain unanswered. Given the state of  
the field it is not possible to accurately speculate on the 
answers to these questions. Additionally there is the 
potential for the modification of  MSCs that further ex-
pands the possible methods of  application
MODIFYING MSC FOR ENHANCED IM-
MUNOSUPPRESSION
The ex vivo manipulation of  MSCs with proinflammatory 
cytokines, particularly IFN-g modification of  MSC en-
hances the immunomodulatory, reparative and homing 
potential of  MSCs[43]. The enhancement of  these MSC 
properties would be beneficial in a transplant setting and 
may hasten the translation of  MSC therapy into SOT 
patients.
Of  key benefit, the priming of  MSCs with IFN-g is 
critical to active MSCs immunosuppressive function[73-75]. 
IFN-g primed MSC have an enhanced ability to sup-
press T cell responses compared to untreated MSC[76-80]. 
Increase suppression of  T cell responses is mediated 
by the induction of  immunosuppressive factors such as 
iNOS andIDO[75,81]. IDO is also well known for its roles 
in preventing rejection and induction tolerance at the 
fetal-maternal interface[82]. In addition, MSC-expressed 
IDO have been shown to induce tolerogenic DCs and 
Tregs[83], which are two other cell based therapies that 
have gained significant interest in SOT, as we have dis-
cussed above. The upregulation of  other MSC immu-
nomodulatory factors, the enhancement of  negative T 
cell signalling, the inhibition of  proinflammatory T cell 
response and the increase in Tregs further support the 
benefits of  administering IFN-g primed MSC therapy 
for SOT. 
Regardless of  the potential therapeutic benefits of  
IFN-g primed MSC therapy, it should be noted that 
IFN-g upregulate MHC class Ⅰ and induces MHC class 
II expression on MSCs[84-86]. This may render these cells 
more immunogenic in MHC-mismatched recipients[43], 
thereby decreasing their effectiveness at suppressing 
inflammation as reported in some studies[87,88]. Only 
two studies have directly addressed IFN-g primed MSC 
immunogenicity in vivo[88,89] and this warrants further in-
vestigation. Thus, when considering IFN-g primed MSC 
therapy, then administration of  autologous MSC may 
be more beneficial. If  allogeneic or third-party IFN-g 
primed MSC were to be considered, the co-administra-
tion of  these cells with immunosuppressive drugs would 
be necessary as an attempt to control anti-donor im-
mune response towards MSC to enable MSCs to exert 
their beneficiary effects in vivo. 
CONCLUSION
In summary, there are numerous cell based therapies that 
have shown potential for use in the immunomodulation 
of  SOT in pre-clinical, small, and large animal models. 
Tregs and DCs have shown promise in vitro and in ani-
mal models as well as displaying safety and efficacy in 
clinical trials involving GVHD, diabetes, and rheumatoid 
arthritis. However, only MSCs have completed large 
clinical trials to date. MSC have shown the most promise 
having been tested in GVHD and in early clinical trials 
for kidney transplantation. Based on the GVHD experi-
ence and the early transplant work, it appears that MSC 
have an acceptable safety profile and potential therapeu-
tic effect. However, much needs to be resolved, includ-
ing the issue of  autologous vs allogeneic (third party 
cells), frequency of  administration and mechanism of  
action. The optimal immunosuppressive therapy to be 
co-administered should also be studied. The results from 
these early trials are positive but have presented numer-
ous issues that need to be addressed before MSCs gain 
widespread clinical use.  
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Table 1  Summary of clinical trials using mesenchymal stem cells in kidney transplantation
Ref. Patient number Cell number Cell source Adverse reactions Graft survival
Tan et al[55], 2012 106 1-2 × 106 cells/kg Autologous, bone marrow None 100% at 1 yr
Perico et al[56], 2011     2 2 × 106 cells/kg Autologous, bone marrow Acute graft dysfunction 100% at 360 d
Perico et al[57], 2013     2 2 × 106 cells/kg Autologous, bone marrow HLA induced rejection 100% at 1 yr
Peng et al[58], 2013     6 5 × 106 1st dose Donor derived, bone marrow None 100% at 1 yr
2 × 106 cells/kg 2nd dose
HLA: Human leukocyte antigen.
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